Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 19, Issue 5, Pages 342-355
Publisher
Springer Science and Business Media LLC
Online
2022-03-23
DOI
10.1038/s41571-022-00607-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
- (2021) Stephan Kadauke et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Lymphoblastic Leukemia: A Population‐ based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results ( SEER ) Database, 1980‐2017
- (2021) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity
- (2021) Gordana Raca et al. LEUKEMIA
- Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
- (2021) Karlo Perica et al. LEUKEMIA
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
- (2021) Shuangyou Liu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
- (2021) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Olalekan O. Oluwole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
- (2021) Li-Chung Tsao et al. CANCER RESEARCH
- Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
- (2021) Belén Blanco et al. CLINICAL CANCER RESEARCH
- Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- (2021) Bijal D. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
- (2021) Kathryn M. Cappell et al. Nature Reviews Clinical Oncology
- Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
- (2021) Nora Liebers et al. Blood Advances
- Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Max S. Topp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience
- (2020) Nathan Denlinger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
- (2020) Paulina Horvei et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- (2020) N. Nora Bennani et al. BLOOD
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
- (2020) Jeremy S. Abramson et al. BLOOD
- Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
- (2020) Michael D. Jain et al. BLOOD
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation
- (2020) Magdi Elsallab et al. LANCET ONCOLOGY
- Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy
- (2020) Diane Libert et al. LEUKEMIA
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma
- (2020) Christopher M. Wright et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Commercial anti‐CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center
- (2020) Pierre Sesques et al. AMERICAN JOURNAL OF HEMATOLOGY
- How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population
- (2020) Stephen P. Hunger et al. BLOOD
- Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
- (2020) Bachar Samra et al. Journal of Hematology & Oncology
- Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas
- (2020) P. Connor Johnson et al. LEUKEMIA & LYMPHOMA
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- Bilateral retinal detachment after chimeric antigen receptor T-cell therapy
- (2020) Christopher C. Denton et al. Blood Advances
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
- (2020) Kathryn M. Cappell et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
- (2020) Bicky Thapa et al. Blood Advances
- Use of cardiac radiation therapy as bridging therapy to CAR‐T for relapsed pediatric B‐cell acute lymphoblastic leukemia
- (2020) Cesar P. Marquez et al. PEDIATRIC BLOOD & CANCER
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues
- (2019) Jérémie Gaudichon et al. BLOOD REVIEWS
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
- (2019) Ankit J. Kansagra et al. BONE MARROW TRANSPLANTATION
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
- (2019) Sandhya R. Panch et al. MOLECULAR THERAPY
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
- (2019) Yaqing Cao et al. Frontiers in Oncology
- A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
- (2019) Sunita Dwivedy Nasta et al. BLOOD
- CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial
- (2019) Ann-Marie E Bröske et al. BLOOD
- Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
- (2019) Caspian Oliai et al. BLOOD
- Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel
- (2019) Ajeet Gajra et al. BLOOD
- Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience
- (2019) Jérôme Paillassa et al. BLOOD
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
- (2019) Charalambos Andreadis et al. BLOOD
- A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
- (2019) Peter A. Riedell et al. BLOOD
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma
- (2019) Kirk E. Cahill et al. LEUKEMIA & LYMPHOMA
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Inmaculada Hernandez et al. JAMA Oncology
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
- (2018) Elad Jacoby et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- (2018) Reith R Sarkar et al. JNCI-Journal of the National Cancer Institute
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous lymphapheresis for the production of chimeric antigen receptor T cells
- (2017) Elizabeth S. Allen et al. TRANSFUSION
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- CAR-T Cell Therapy for Lymphoma
- (2016) Carlos A. Ramos et al. Annual Review of Medicine
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- CAR-T Cell Therapies From the Transfusion Medicine Perspective
- (2016) Andrew Fesnak et al. TRANSFUSION MEDICINE REVIEWS
- The Cell Killing Mechanisms of Hydroxyurea
- (2016) Amanpreet Singh et al. Genes
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
- (2015) Ching-Hon Pui et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Opportunities and challenges of radiotherapy for treating cancer
- (2015) Dörthe Schaue et al. Nature Reviews Clinical Oncology
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia
- (2014) Kjeld Schmiegelow et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Diffuse large B-cell lymphoma
- (2013) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Asparaginases
- (2011) Vassilios I. Avramis JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
- CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
- (2009) A Takeshita et al. LEUKEMIA
- Cyclophosphamide and cancer: golden anniversary
- (2009) Ashkan Emadi et al. Nature Reviews Clinical Oncology
- Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
- (2008) J. Cai et al. CANCER RESEARCH
- Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
- (2008) H. Konig et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More